Clinical Trials Sponsored by Abiogen Pharma

Total 8999 results

Uni-Pharma
Biogen

Completed

Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

Chronic Plaque Psoriasis
UCB Pharma
Biogen

Terminated

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Multiple Sclerosis

United States, France, Germany, Spain, Canada, Netherlands, Belgium, Hungary, Sweden, United Kingdom, Finland
UCB Pharma
Biogen

Completed

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Immune System Diseases | Autoimmune Diseases | Lupus Erythematosus, Systemic | Skin and Connective Tissue Diseases | Connective Tissue Disease

Bulgaria, Belgium, Germany, Poland, Romania, Russian Federation, Spain
UCB Pharma
Biogen

Completed

CDP323 Biomarker Study

Relapsing Multiple Sclerosis

United Kingdom
Astellas Pharma Inc
Biogen

Completed

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Psoriatic Arthritis

Poland, Canada, United States, Russian Federation, Germany
Astellas Pharma Inc
Biogen

Completed

Community Based Trial for AMEVIVE®

Moderate to Severe Chronic Plaque Psoriasis

United States
Astellas Pharma Inc
Biogen

Completed

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

Chronic Plaque Psoriasis

United States, Austria, Germany, Belgium, Canada
Aerogen Pharma Limited

Completed

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

Pulmonary Hypertension

United States
Astellas Pharma Inc
Biogen

Completed

Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

Psoriasis

Belgium, Spain, Germany, United States, France, Canada, Denmark, Netherlands, United Kingdom
Astellas Pharma Inc
Biogen

Completed

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Canada
M.D. Anderson Cancer Center
Abiogen Pharma

Terminated

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Chronic Myelogenous Leukemia

United States
Aerogen Pharma Limited

Active, not recruiting

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

Respiratory Distress Syndrome in Premature Infant

United States, Canada
Biogen
GB Pharma Services & Consulting s.r.l.

Withdrawn

Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis (PROMPT)

Relapsing Remitting Multiple Sclerosis
Azienda Unita' Sanitaria Locale Di Modena
Abiogen Pharma

Unknown

Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels (ECSPLOIT -D)

Heart Failure | Vitamin D Deficiency

Italy
AryoGen Pharmed Co.

Completed

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Factor VII Deficiency | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Glanzmann's Thrombasthenia

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency

Factor VII Deficiency

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

AryoTrust® (Trastuzumab) Safety Study

Breast Cancer

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors

Hemophilia A or B With Inhibitor

Iran, Islamic Republic of, Turkey
AryoGen Pharmed Co.

Completed

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA)

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Iran, Islamic Republic of
AryoGen Pharmed Co.

Unknown

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women

Osteoporosis

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Malignant Neoplasm of Breast

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects

Bioequivalence | Phase 1

Iran, Islamic Republic of
Azienda di Servizi alla Persona di Pavia
Abiogen Pharma

Recruiting

Omega 3, Leucine, Probiotic Lactobacillus Paracasei PS23 on Muscle Mass in Sarcopenic Subjects

Sarcopenia | Elderly | Omega 3

Italy
Aerogen Pharma Limited
Ohio State University

Completed

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation (VPCOVID)

COVID-19

United States
Biogen

Not yet recruiting

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer
Biogen

Not yet recruiting

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Multiple Sclerosis
Biogen

Recruiting

Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy (REALITY)

Spinal Muscular Atrophy (SMA)

France
Biogen

Recruiting

A Study for Tysabri Participant Preference

Relapsing-Remitting Multiple Sclerosis (RRMS)

Germany
Biogen

Recruiting

A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam (ASCEND)

Spinal Muscular Atrophy

United States, Germany, Italy, Hungary, Japan
Biogen

Recruiting

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-2)

Lupus Erythematosus, Systemic

China, United States, Belgium, Netherlands, Japan, Romania, Serbia, Canada, Germany, Hungary, Italy, Puerto Rico, Israel, Argentina, Colombia, Czechia, United Kingdom
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Spain, Germany, Croatia, Turkey, Saudi Arabia, Hungary, Belgium, Australia, France, Portugal, Slovakia, United States, Bulgaria, Greece, Kuwait, Russian Federation, Tunisia, Italy, Argentina, Czechia, Israel, Serbia
Biogen

Active, not recruiting

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy (DEVOTE)

Muscular Atrophy, Spinal

China, United States, Netherlands, Spain, Korea, Republic of, Taiwan, Australia, Canada, Chile, Saudi Arabia, Poland, Israel, Brazil, Russian Federation, Hungary, Japan, United Kingdom, Italy, Germany, Estonia, Greece, Mexico, Colombia and more
Biogen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

Healthy Volunteers

United States
Biogen

Completed

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Progressive Multifocal Leukoencephalopathy

United States
Biogen

Enrolling by invitation

A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)

Subacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus Erythematosus

Spain, United States, Sweden
Biogen

Enrolling by invitation

Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen (ONWARD)

Muscular Atrophy, Spinal

United States, Spain, Taiwan, Chile, Saudi Arabia, Brazil, Russian Federation, Mexico, Germany, Estonia, Japan, Canada, Colombia, Lebanon, Poland, Italy, China
Biogen

Completed

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (TYPIFI)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Healthy Volunteer

United Kingdom, Sweden
Biogen

Completed

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)

X-Linked Retinitis Pigmentosa

United States, United Kingdom
Biogen

Terminated

A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion (ASTRAL)

Brain Contusion

Israel, Spain, United States, Germany, Italy, Japan, France
Biogen

Terminated

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

Insomnia | Major Depressive Disorder

United States
Biogen

Completed

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

Healthy

United States
Biogen

Terminated

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Major Depressive Disorder

United States
Biogen

Completed

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) (LILAC)

Systemic Lupus Erythematosus | Active Cutaneous Lupus Erythematosus

United States, Taiwan, Philippines, Argentina, Poland, Israel, Bulgaria, Serbia, Mexico, Colombia, Korea, Republic of, Thailand
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Biogen

Completed

Efficacy and Safety of BG00012 in MS

Multiple Sclerosis

Russian Federation, Sweden, Germany, Poland, Hungary, United Kingdom, Netherlands, Switzerland, Turkey, Czechia

3

Subscribe